Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.600
+0.120 (3.45%)
At close: Feb 6, 2026, 4:00 PM EST
3.590
-0.010 (-0.28%)
After-hours: Feb 6, 2026, 7:31 PM EST
Grace Therapeutics Employees
Grace Therapeutics had 6 employees as of March 31, 2025. The number of employees increased by 2 or 50.00% compared to the previous year.
Employees
6
Change (1Y)
2
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,303,333
Market Cap
55.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 6 | 2 | 50.00% |
| Mar 31, 2024 | 4 | -28 | -87.50% |
| Mar 31, 2020 | 32 | 4 | 14.29% |
| Mar 31, 2019 | 28 | 17 | 154.55% |
| Feb 29, 2016 | 11 | 4 | 57.14% |
| Feb 28, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| ImmuCell | 84 |
| Acrivon Therapeutics | 78 |
| PMV Pharmaceuticals | 47 |
| Instil Bio | 14 |
| Cingulate | 13 |
| Nutriband | 13 |
GRCE News
- 2 months ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 3 months ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 4 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire
- 5 months ago - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - GlobeNewsWire
- 5 months ago - Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 - GlobeNewsWire